Browsing Tag
AstraZeneca
154 posts
Why off-the-shelf CAR T therapies are attracting billion-dollar deals despite early-stage risks
Big pharma is betting billions on off-the-shelf CAR T therapies. Can allogeneic platforms overcome early-stage risks to transform cancer care?
Why amylin is gaining pharma attention in obesity drug development: From amycretin to AZD6234
Discover how Novo Nordisk, AstraZeneca, and others are betting on amylin-based obesity drugs like amycretin and AZD6234 to reshape metabolic care.
The oral biologics revolution: How macrocyclic peptides could reshape drug delivery
Macrocyclic peptides are revolutionizing oral biologics. Explore how Merck, Protagonist, and others are turning injectables into convenient, high-impact pills.
Can IonQ become the Nvidia of quantum computing? What the Oxford Ionics deal signals about platform consolidation
IonQ’s deal to acquire Oxford Ionics marks a strategic shift toward becoming the “Nvidia of quantum.” Explore what this means for quantum computing’s future.
Quantum leap: IonQ targets Oxford Ionics in $1bn+ deal to hit 2 million qubits by 2030
IonQ’s $1.075B acquisition of Oxford Ionics boosts its bid for fault-tolerant quantum systems by 2030. Find out what this means for the industry.
How AI is transforming cancer diagnosis and treatment planning in 2025
AI is reshaping cancer care—improving diagnosis, guiding treatment, and boosting efficiency across hospitals. Discover how it's redefining oncology workflows in 2025.
Checkpoint inhibitors in early-stage cancer: A new era of adjuvant therapy is taking shape
Checkpoint inhibitors are redefining early-stage cancer care. Find out how Tecentriq, Keytruda, and others are competing for the adjuvant immunotherapy market.
Racing to save lives: Indy 500 and NASCAR drivers unite to fight prostate cancer in veterans
Find out how ZERO Prostate Cancer and racing legends are spotlighting veterans’ health at Indy 500 and NASCAR this Memorial Day weekend.
AstraZeneca’s $13.6bn Q1 2025 sales surge as cancer drugs and AI deals set stage for $80bn goal
Explore how AstraZeneca’s strong Q1 2025 results, new drug approvals, and AI-powered R&D are reshaping its global growth story.
Imfinzi gains EU approval in resectable NSCLC, bolstering AstraZeneca’s oncology pipeline
AstraZeneca’s Imfinzi-based regimen approved in the EU to cut lung cancer recurrence by 32%—learn how this could redefine early-stage NSCLC treatment.